Status:
UNKNOWN
Post-RAI Therapy Dosimetry and Quality Assessment of Target Tissue Dosing
Lead Sponsor:
State University of New York - Upstate Medical University
Conditions:
Thyroid Disease
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this clinical trial study is to(1) determine the tissue specific dose of I-131 taken up by residing thyroid issue in the thyroid bed post-RAI along with any other sites in the neck and med...
Detailed Description
In our current clinical practice, patients with well-differentiated thyroid cancer (DTC) who receive oral administration of radioiodine 1-131 (RAI) have whole body and planar images obtained 4-5 days ...
Eligibility Criteria
Inclusion
- All minorities
- 18 years of age and older
- Ability to give consent
- Male or female
- Differentiated thyroid cancer (DTC)
- Previous total thyroidectomy
- Has either:
- local lymph node metastases
- distant mediastinal/cervical metastases
- lung or osseous metastases as seen on prior imaging studies
Exclusion
- Non-iodine avid disease
- Under 18 years of age
- Unable to give consent
- Pregnant women, Non-viable neonates or neonates of uncertain viability.
- Non-English-speaking patients
Key Trial Info
Start Date :
November 8 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 8 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06028282
Start Date
November 8 2021
End Date
June 8 2025
Last Update
December 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SUNY Upstate Medical University
Syracuse, New York, United States, 13210